Nai-Kong V. Cheung, MD, PhD
Head, Neuroblastoma Program; Enid A. Haupt Chair in Pediatric Oncology
Pediatric Oncology; Neuroblastoma and Developmental Tumors of Childhood; Immunotherapy; Autologous Bone Marrow Transplantation
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Accepted Insurance Providers
Dr. Cheung accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- The Empire Indemnity Plan provides limited coverage for our services.
Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, and HMO plans as well as their Enhanced Care Prime Network, which supports Medicaid Managed Care and Child Health Plus plans. Memorial Sloan Kettering is also in-network with the New York State Essential Emblem Health plan, which can be purchased on the insurance exchange. Emblem Health does not include us in any of its Medicare plans or in any of its Select Care network plans. You must bring a referral from your Emblem primary care doctor to your first appointment.
Formerly known as Health Plus Amerigroup, Empire Blue Cross Blue Shield Health Plus is an in-network provider with Memorial Sloan Kettering. You will need a one-time referral from your primary care doctor.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We're here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with Medicaid NY Emblem Health (formerly known as HIP) and Medicaid NY Empire Blue Cross Blue Shield HealthPlus (formerly known as Amerigroup). You will need a one-time referral from your primary care doctor.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar's Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plansas well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford's Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Contact and Location
Find a Convenient Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, Harvard Medical School; PhD, Harvard Medical School
Pediatrics - Stanford University
Pediatric Hematology/Oncology - Stanford University
Pediatrics; Pediatric Hematology-Oncology
I am a pediatric oncologist who specializes in immunologic approaches for the diagnosis and treatment of pediatric cancers. My main focus is the treatment of neuroblastoma, a tumor that arises from primitive cells of the sympathetic nervous system and that primarily affects young children.
My colleagues and I have developed multi-modality therapies, which include surgery, chemotherapy, radiation therapy, isotretinoin (a vitamin A derivative), and more importantly, targeted therapy with monoclonal antibodies. These treatment strategies have dramatically improved the survival for our patients with metastatic neuroblastoma. Today, more than 50 percent of these patients treated at Memorial Sloan Kettering survive the disease, compared to fewer than 5 percent in the 1980s. In fact, immunotherapy has now become the standard of care for patients with metastatic neuroblastoma. Moreover, localized neuroblastoma is curable today, and many patients with can be treated effectively with surgery alone.
We are also actively involved in early clinical trials of novel therapies, including biologic agents and vaccines, natural killer cells, and combinations of these novel therapies with conventional treatments. We hope that effective strategies for neuroblastoma will provide a paradigm for other metastatic solid tumors affecting children and adolescents.
In the laboratory we are evaluating markers of minimal residual disease, which may predict early metastasis and recurrence; discovering novel tumor targets; and engineering next-generation antibodies to make them more potent and “human-like,” as well as arming these antibodies with either T lymphocytes or powerful radioactive isotopes for the diagnosis and treatment of neuroblastoma. We believe many of these novel antibodies have potential applications for other solid tumors in adolescents and even in adults.
We are screening new drugs that can overcome the resistance that neuroblastoma often develops after prolonged treatment with chemotherapy. We are also trying to unmask the genetic and biochemical makeup of neuroblastoma tumors to determine if the tumor profile at the time of diagnosis, metastasis, or relapse can tell us how aggressive a tumor may be, and what kind of therapy may be most effective. Our major thrust continues to be the translation of novel therapies to help our patients.
The team of experts at Memorial Sloan Kettering treats more patients with neuroblastoma than at any other institution in the world. With evidence-based treatment approaches, our expertise translates to better patient outcomes. Families who come to us benefit from the dedication and compassion of individuals from various disciplines who share the vision and the desire to eradicate this devastating disease.
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials Investigated by Dr. Cheung
- Molecular Characterization of Neuroblastic Tumors and Clinical Outcome
Find a Clinical Trial for You
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NV, Larson SM, Dunkel IJ. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018 Jun 15. pii: S1470-2045(18)30322-X. doi: 10.1016/S1470-2045(18)30322-X.
Kushner BH, Cheung IY, Modak S, Basu EM, Roberts SS, Cheung NK. Humanized 3F8 anti-GD2 monoclonal antibody dosing with granulocyte-macrophage colony-stimulating factor in patients with resistant neuroblastoma – A Phase 1 Clinical Trial. JAMA Oncol. 2018 September 20. doi:10.1001/jamaoncol.2018.4005
Wu ZH, Guo HF, Xu H, Cheung NKV. Development of a tetravalent anti-GPA33/anti-CD3 bispecific antibody for colorectal cancers. Mol Cancer Ther. 2018 Aug 6. pii: molcanther.0026.2018. doi: 10.1158/1535-7163.MCT-18-0026.
Ahmed M, Lopez-Albaitero A, Pankov D, Santich BH, Liu H, Yan S, Xiang J, Wang P, Hasan AH, Selvakumar A, O’Reilly RJ, Liu C, Cheung NKV. TCR-mimic bispecific antibodies targeting LMP2A show potent activity against EBV malignancies. JCI Insight. 2018 Feb 22;3(4). pii: 97805. doi: 10.1172/jci.insight.97805.
Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Wittrup KD, Cheung NKV, Larson SM. Curative multi-cycle radioimmunotherapy monitored by quantitative SPECT/CT-based theranostics, using bispecific antibody pretargeting strategy in colorectal cancer. Journal of Nuclear Medicine 58(11):1735-1742, 2017.
Hoseini SS, Dobrenkov K, Pankov D, Xu XL, and Cheung NK. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2. Oncoimmunology. 2017;6(6):e1320625.
Lopez-Albaitero A, Xu H, Guo HF, Wang LL, Wu Z, Tran H, Chandarlapaty S, Scaltriti M, Janjigian Y, de Stanchina E, and Cheung NK. Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody. OncoImmunology 2017 10;6(3):e1267891. doi: 10.1080/2162402X.2016.1267891. eCollection 2017.
Zhao Q, Ahmed M, Tassev DV, Hasan A, Kuo TY, Guo HF, O’Reilly RJ and Cheung NK. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential. Leukemia;29(11):2238-2247, 2015.
Zhao Q, Ahmed M, Guo HF, Cheung IY, and Cheung NK. Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8. Journal of Biological Chemistry 290:13017-13027, 2015.
Ahmed M, Cheng M, Zhao Q, Yehuda G, Cheal SM, Guo HF, Larson SM, and Cheung NK. Humanized Affinity-Matured Monoclonal Antibody 8H9 Has Potent Anti-Tumor Activity and Binds to FG Loop of B7-H3. Journal of Biological Chemistry 290(50):30018-30029, 2015.
Publications on PubMed
Visit PubMed for a full listing of Dr. Cheung’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.